ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Down 13.4% in May

ALX Oncology Holdings Inc. (NASDAQ:ALXOGet Free Report) saw a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 2,910,000 shares, a drop of 13.4% from the May 15th total of 3,360,000 shares. Based on an average daily volume of 671,300 shares, the short-interest ratio is currently 4.3 days. Approximately 10.0% of the company’s shares are sold short.

ALX Oncology Trading Down 8.3 %

Shares of NASDAQ ALXO opened at $7.38 on Tuesday. The stock has a market cap of $384.50 million, a price-to-earnings ratio of -1.98 and a beta of 1.16. The business has a 50 day simple moving average of $13.37 and a 200 day simple moving average of $13.48. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.21 and a current ratio of 5.21. ALX Oncology has a 52 week low of $3.94 and a 52 week high of $17.83.

ALX Oncology (NASDAQ:ALXOGet Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.16. On average, research analysts predict that ALX Oncology will post -2.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of ALX Oncology in a research report on Monday, June 10th. Stifel Nicolaus reiterated a “hold” rating and set a $14.00 target price (up previously from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research note on Wednesday, May 29th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $19.67.

View Our Latest Analysis on ALXO

Insider Buying and Selling at ALX Oncology

In related news, insider Jaume Pons sold 20,000 shares of ALX Oncology stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $11.15, for a total value of $223,000.00. Following the transaction, the insider now owns 628,359 shares in the company, valued at $7,006,202.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO Peter S. Garcia purchased 12,000 shares of the firm’s stock in a transaction on Thursday, June 13th. The stock was purchased at an average price of $8.53 per share, for a total transaction of $102,360.00. Following the acquisition, the chief financial officer now directly owns 122,348 shares in the company, valued at $1,043,628.44. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jaume Pons sold 20,000 shares of the business’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $11.15, for a total transaction of $223,000.00. Following the completion of the transaction, the insider now owns 628,359 shares in the company, valued at approximately $7,006,202.85. The disclosure for this sale can be found here. Insiders have sold a total of 122,000 shares of company stock worth $1,611,280 in the last quarter. 33.40% of the stock is owned by insiders.

Hedge Funds Weigh In On ALX Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CANADA LIFE ASSURANCE Co acquired a new position in shares of ALX Oncology during the first quarter worth approximately $27,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of ALX Oncology during the fourth quarter worth approximately $28,000. EntryPoint Capital LLC acquired a new stake in shares of ALX Oncology in the 1st quarter valued at $32,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of ALX Oncology by 445.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock valued at $86,000 after acquiring an additional 4,706 shares during the period. Finally, J.P. Morgan Private Wealth Advisors LLC bought a new position in shares of ALX Oncology in the 3rd quarter valued at about $96,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

About ALX Oncology

(Get Free Report)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.

Featured Stories

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.